CERo Therapeutics (CERO) announced that investigators have been authorized under the study protocol to administer a third infusion of CER-1236 to a patient enrolled in the first cohort of its ongoing Phase 1 clinical trial. This additional infusion of 1 million CER-1236 cells per kilogram of body weight of the patient — completed approximately one week ago and identical to the first two doses — is intended to generate further safety and dosing information that may help assess the feasibility of a multi-dose administration strategy as an alternative to a single, higher-dose approach. The initial dose level for Cohort One was selected based on dose ranges commonly used in other adoptive T-cell therapy studies.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Expands Securities Purchase Agreement
- CERo Therapeutics Enters Securities Purchase Agreement
- Cero Therapeutics completes first cohort of Phase 1 trial of CER-1236 in AML
- Cero Therapeutics ‘open’ to takeover bids, Axios reports
- CERo Therapeutics Updates Corporate Presentation on Innovations